EMILY ROUNTREE: Open Payments
NPI 1477635605 · CHARLESTON, SC. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$759 in 32 payments from 11 companies in 2025. Trend: 2023 $1,228 · 2024 $1,324 · 2025 $759
Food & beverage: $759
| Company | Payments | Amount |
|---|---|---|
| E.R. Squibb & Sons, L.L.C. | 6 | $132 |
| Teva Pharmaceuticals USA, Inc. | 4 | $116 |
| Alkermes, Inc. | 5 | $112 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 4 | $81 |
| Neurocrine BioSciences, Inc. | 3 | $75 |
| ABBVIE INC. | 3 | $63 |
| Lundbeck LLC | 2 | $54 |
| Otsuka America Pharmaceutical, Inc. | 2 | $51 |
| Janssen Pharmaceuticals, Inc | 1 | $29 |
| Noven Therapeutics, LLC | 1 | $24 |
Products named: COBENFY, REXULTI, ARISTADA, CAPLYTA, UZEDY, INGREZZA, VRAYLAR, INVEGA SUSTENNA.
Industry payments across SC — which companies pay providers there.
